Abstract:Concurrent neurodegenerative and vascular pathologies pose a diagnostic challenge in the clinical setting, with histopathology remaining the definitive modality for dementia-type diagnosis. To address this clinical challenge, we introduce a neuropathology-based, data-driven, multi-label deep learning framework to identify and quantify in-vivo biomarkers for Alzheimer's disease (AD), vascular dementia (VD), and Lewy body dementia (LBD) using antemortem T1-weighted MRI scans of 423 demented and 361 control participants from NACC and ADNI datasets. Based on the best-performing deep learning model, explainable heatmaps are extracted to visualize disease patterns, and the novel Deep Signature of Pathology Atrophy REcognition (DeepSPARE) indices are developed, where a higher DeepSPARE score indicates more brain alterations associated with that specific pathology. A substantial discrepancy in clinical and neuropathology diagnosis was observed in the demented patients: 71% of them had more than one pathology, but 67% of them were clinically diagnosed as AD only. Based on these neuropathology diagnoses and leveraging cross-validation principles, the deep learning model achieved the best performance with a balanced accuracy of 0.844, 0.839, and 0.623 for AD, VD, and LBD, respectively, and was used to generate the explainable deep-learning heatmaps and DeepSPARE indices. The explainable deep-learning heatmaps revealed distinct neuroimaging brain alteration patterns for each pathology: the AD heatmap highlighted bilateral hippocampal regions, the VD heatmap emphasized white matter regions, and the LBD heatmap exposed occipital alterations. The DeepSPARE indices were validated by examining their associations with cognitive testing, neuropathological, and neuroimaging measures using linear mixed-effects models. The DeepSPARE-AD index was associated with MMSE, Trail B, memory, PFDR-adjustedhippocampal volume, Braak stages, CERAD scores, and Thal phases (PFDR-adjusted < 0.05). The DeepSPARE-VD index was associated with white matter hyperintensity volume and cerebral amyloid angiopathy (PFDR-adjusted < 0.001). The DeepSPARE-LBD index was associated with Lewy body stages (PFDR-adjusted < 0.05). The findings were replicated in an out-of-sample ADNI dataset by testing associations with cognitive, imaging, plasma, and CSF measures. CSF and plasma pTau181 were significantly associated with DeepSPARE-AD in the AD/MCIΑβ+ group (PFDR-adjusted < 0.001), and CSF α-synuclein was associated solely with DeepSPARE-LBD (PFDR-adjusted = 0.036). Overall, these findings demonstrate the advantages of our innovative deep-learning framework in detecting antemortem neuroimaging signatures linked to different pathologies. The newly deep learning-derived DeepSPARE indices are precise, pathology-sensitive, and single-valued noninvasive neuroimaging metrics, bridging the traditional widely available in-vivo T1 imaging with histopathology.

Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer's disease

Deep Learning‐based Identification of Transcriptomic Signatures Associated with Alzheimer’s Disease Progression

Integrative Network Analysis of Nineteen Brain Regions Identifies Molecular Signatures and Networks Underlying Selective Regional Vulnerability to Alzheimer’s Disease

Single-cell RNA sequencing analysis of human Alzheimer’s disease brain samples reveals neuronal and glial specific cells differential expression

Elucidating the neuropathological and molecular heterogeneity of amyloid-beta and tau in Alzheimer's disease through machine learning and transcriptomic integration

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Discovery of disease‐associated, tau, and inflammatory microglial subpopulations and molecular drivers in Alzheimer’s disease using network‐based deep learning integration of human brain single‐cell RNA‐sequencing data

Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

Systems genetic dissection of Alzheimer's disease brain gene expression networks

Systematic Analysis to Identify Transcriptome-Wide Dysregulation of Alzheimer’s Disease in Genes and Isoforms

Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias

Disentangling brain heterogeneity via semi‐supervised deep‐learning and MRI: Application to dimensional representations of Alzheimer’s disease

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases

A public resource of single cell transcriptomes and multiscale networks from persons with and without Alzheimer’s disease

A Network‐based Deep Learning Framework Translates GWAS and Multi‐Omics Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease

Detecting Diagnostic Biomarkers of Alzheimer's Disease by Integrating Gene Expression Data in Six Brain Regions

An integrated brain-specific network identifies genes associated with neuropathologic and clinical traits of Alzheimer’s disease

Single-cell transcriptomic analysis of Alzheimer’s disease

Identification of diagnostic signatures associated with immune infiltration in Alzheimer's disease by integrating bioinformatic analysis and machine-learning strategies

Identification of biomarkers of Alzheimer's disease and their characterization of immune function

Single-nucleus and spatial transcriptomic profiling of human temporal cortex and white matter reveals novel associations with AD pathology